Abstract
Pharmaceutical policy in Canada is set at both the federal and provincial levels of government. The federal government is responsible for intellectual property rights of manufacturers (patents) and the initial approval and labelling of prescription drugs and for ensuring overall market competitiveness. The provincial government has responsibility and jurisdiction over the funding of all health care services, including pharmaceuticals. Various interactions between the pharmaceutical industry, the federal and provincial governments and consumers have shaped the current landscape for prescription drugs in Canada. One key failing of the system is that the federal government is almost completely insulated from the impact of its policies because, although it regulates drug prices, it does not buy any drugs. In contrast, provincial governments have no jurisdiction over market competitiveness or pricing, yet end up paying for most of the drug expenditures incurred.
Full Text
The Full Text of this article is available as a PDF (194.1 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Anis A. H. Substitution laws, insurance coverage, and generic drug use. Med Care. 1994 Mar;32(3):240–256. doi: 10.1097/00005650-199403000-00005. [DOI] [PubMed] [Google Scholar]
- Anis A. H., Wen Q. Price regulation of pharmaceuticals in Canada. J Health Econ. 1998 Jan;17(1):21–38. doi: 10.1016/s0167-6296(97)00016-7. [DOI] [PubMed] [Google Scholar]
- Bourgault C., Elstein E., Le Lorier J., Suissa S. Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors. CMAJ. 1999 Aug 10;161(3):255–260. [PMC free article] [PubMed] [Google Scholar]
- Detsky A. S. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada. Pharmacoeconomics. 1993 May;3(5):354–361. doi: 10.2165/00019053-199303050-00003. [DOI] [PubMed] [Google Scholar]
- Lipsy R. J. Institutional formularies: the relevance of pharmacoeconomic analysis to formulary decisions. Pharmacoeconomics. 1992 Apr;1(4):265–281. doi: 10.2165/00019053-199201040-00004. [DOI] [PubMed] [Google Scholar]
- Narine L., Senathirajah M., Smith T. Evaluating reference-based pricing: initial findings and prospects. CMAJ. 1999 Aug 10;161(3):286–288. [PMC free article] [PubMed] [Google Scholar]
- Torrance G. W., Blaker D., Detsky A., Kennedy W., Schubert F., Menon D., Tugwell P., Konchak R., Hubbard E., Firestone T. Canadian guidelines for economic evaluation of pharmaceuticals. Canadian Collaborative Workshop for Pharmacoeconomics. Pharmacoeconomics. 1996 Jun;9(6):535–559. doi: 10.2165/00019053-199609060-00008. [DOI] [PubMed] [Google Scholar]